Implementation of Oncotype Dx to Guide Chemotherapy Sparing for Women with Postmenopausal N1-3, ER-positive, HER-2-negative Breast Cancer

被引：0
|
作者：
Rajakumar, L. [1 ]
Glendenning, J. [1 ]
Hall, J. [1 ]
Burcombe, R. [1 ]
McCormick, G. [1 ]
Hegarty, G. [1 ]
Harper-Wynne, C. [1 ]
Brown, B. [1 ]
Moss, C. [1 ]
Thomas, C. [1 ]
Jyothirmayi, R. [1 ]
Osman, M. [1 ]
Nikiforidis, L. [1 ]
机构：
[1] Maidstone & Tunbridge Wells NHS Trust, Maidstone, Kent, England
来源：
CLINICAL ONCOLOGY | 2024年 / 36卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：E111 / E111
页数：1
相关论文
共 50 条
  • [41] ASO Author Reflections: Oncotype DX RS Complementing the Prognostic Stage in the Updated AJCC 8th Edition for T1-2N1M0 ER-Positive HER2-Negative Breast Cancer
    Maoli Wang
    Kejin Wu
    Hongliang Chen
    Annals of Surgical Oncology, 2019, 26 : 1236 - 1237
  • [42] Survival is associated with complete response on MRI after neoadjuvant chemotherapy in ER-positive HER2-negative breast cancer
    Loo, Claudette E.
    Rigter, Lisanne S.
    Pengel, Kenneth E.
    Wesseling, Jelle
    Rodenhuis, Sjoerd
    Peeters, Marie-Jeanne T. F. D. Vrancken
    Sikorska, Karolina
    Gilhuijs, Kenneth G. A.
    BREAST CANCER RESEARCH, 2016, 18
  • [43] Survival is associated with complete response on MRI after neoadjuvant chemotherapy in ER-positive HER2-negative breast cancer
    Claudette E. Loo
    Lisanne S. Rigter
    Kenneth E. Pengel
    Jelle Wesseling
    Sjoerd Rodenhuis
    Marie-Jeanne T. F. D. Vrancken Peeters
    Karolina Sikorska
    Kenneth G. A. Gilhuijs
    Breast Cancer Research, 18
  • [44] Prediction of benefit from chemotherapy in ER-positive/HER2-negative breast cancer-a problem still to be solved
    Schmidt, M.
    Untch, M.
    ANNALS OF ONCOLOGY, 2014, 25 (03) : 754 - 754
  • [45] FDG PET/CT during neoadjuvant chemotherapy may predict response in ER-positive/HER2-negative and triple negative, but not in HER2-positive breast cancer
    Koolen, Bas B.
    Pengel, Kenneth E.
    Wesseling, Jelle
    Vogel, Wouter V.
    Peeters, Marie-Jeanne T. F. D. Vrancken
    Vincent, Andrew D.
    Gilhuijs, Kenneth G. A.
    Rodenhuis, Sjoerd
    Rutgers, Emiel J. Th.
    Olmos, Renato A. Valdes
    BREAST, 2013, 22 (05): : 691 - 697
  • [46] FDG PET/CT during neoadjuvant chemotherapy may predict response in ER-positive/HER2-negative and triple negative, but not in HER2-positive breast cancer
    Koolen, B. B.
    Pengel, K. E.
    Wesseling, J.
    Vogel, W. V.
    Peeters, M. T. F. D. Vrancken
    Vincent, A. D.
    Gilhuijs, K. G. A.
    Rodenhuis, S.
    Rutgers, E. J. T.
    Olmos, R. A. Valdes
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2012, 39 : S226 - S226
  • [47] New Treatment Options in ER-Positive, HER2-Positive and Triple-Negative Breast Cancer
    Steger, Guenther
    Bell, Richard
    Cameron, David
    Dent, Rebecca A.
    Jackisch, Christian
    BREAST CARE, 2013, 8 (02) : 155 - 157
  • [48] Clinical Validation of EndoPredict in Pre-Menopausal Women with ER-Positive, HER2-Negative Primary Breast Cancer
    Constantinidou, Anastasia
    Marcou, Yiola
    Toss, Michael S.
    Simmons, Timothy
    Bernhisel, Ryan
    Hughes, Elisha
    Probst, Braden
    Meek, Stephanie
    Kakouri, Eleni
    Georgiou, Georgios
    Zouvani, Ioanna
    Savvidou, Gabriella
    Kuhl, Vanessa
    Doedt, Jennifer
    Wagner, Susanne
    Gutin, Alexander
    Slavin, Thomas P.
    Lanchbury, Jerry S.
    Kronenwett, Ralf
    Ellas, Ian O.
    Rakha, Emad A.
    CLINICAL CANCER RESEARCH, 2022, 28 (20) : 4435 - 4443
  • [49] HER2 equivocal breast cancer that is positive by alternative probe HER2 FISH are classified as HER2 negative by Oncotype DX
    Tozbikian, Gary H.
    Zynger, Debra L.
    BREAST JOURNAL, 2018, 24 (04): : 535 - 540
  • [50] GSTM1 polymorphism in Oncotype DX assay can predict response to taxane-based neoadjuvant chemotherapy in ER-positive Chinese breast cancer patients
    Liao, N.
    Qian, X. K.
    Ren, C. Y.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : S55 - S56
12345